Antisense and RNAi Therapeutics Market Revenue 2024 to 2034
Antisense and RNAi Therapeutics Market Revenue 2024 to 2034
The global antisense and RNAi therapeutics market size is expected to increase from USD 7.38 billion in 2025 to USD 35.63 billion by 2034, growing at a CAGR of 19.12% throughout the forecast period from 2025 to 2034.
Report ID: 10181
|
Format: Databook
|
Published: August 2025
|
Delivery: Immediate
Download Sample
Customisation Request
Revenue,
USD USD 6.19 Bn
Forecast Year,
USD USD 35.63 Bn
CAGR, 2025 -
19.12%
Report Coverage
Worldwide
Reviewed By
Aditi Shivarkar
Reviewed By
Aman Singh
Antisense and RNAi Therapeutics Market Size Analysis
Antisense and RNAi Therapeutics Market Size By Technology 2024 to 2034 (USD )
| Technology | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RNA Interference | 3404.50 | 4059.13 | 4839.62 | 5770.19 | 6879.68 | 8202.50 | 9779.66 | 11660.07 | 13902.02 | 16575.03 | 19761.98 |
| Antisense RNA | 2785.50 | 3314.40 | 3943.72 | 4692.53 | 5583.51 | 6643.66 | 7905.08 | 9406.00 | 11191.88 | 13316.82 | 15845.19 |
Antisense and RNAi Therapeutics Market Size By Application 2024 to 2034 (USD )
| Application | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Genetic Disease | 1238.00 | 1477.66 | 1763.70 | 2105.10 | 2512.58 | 2998.92 | 3579.39 | 4272.20 | 5099.08 | 6085.98 | 7263.86 |
| Cancer | 1114.20 | 1329.45 | 1586.27 | 1892.71 | 2258.33 | 2694.58 | 3215.09 | 3836.13 | 4577.13 | 5461.24 | 6516.11 |
| Infectious Disease | 928.50 | 1103.82 | 1312.23 | 1559.99 | 1854.52 | 2204.65 | 2620.88 | 3115.67 | 3703.86 | 4403.07 | 5234.25 |
| Neurodegenerative Disorders | 742.80 | 887.04 | 1059.27 | 1264.94 | 1510.54 | 1803.81 | 2154.00 | 2572.17 | 3071.49 | 3667.73 | 4379.68 |
| Cardiometabolic & Renal Disorders | 619.00 | 735.88 | 874.82 | 1039.99 | 1236.35 | 1469.77 | 1747.25 | 2077.11 | 2469.24 | 2935.38 | 3489.50 |
| Ocular Disorders | 495.20 | 591.36 | 706.18 | 843.30 | 1007.03 | 1202.54 | 1436.00 | 1714.78 | 2047.66 | 2445.15 | 2919.79 |
| Respiratory Disorders | 557.10 | 661.41 | 785.23 | 932.23 | 1106.73 | 1313.88 | 1559.79 | 1851.71 | 2198.23 | 2609.56 | 3097.82 |
| Skin Disorders | 495.20 | 586.93 | 695.64 | 824.46 | 977.11 | 1158.00 | 1372.34 | 1626.30 | 1927.21 | 2283.74 | 2706.15 |
Antisense and RNAi Therapeutics Market Size By Route of Administration 2024 to 2034 (USD )
| Route of Administration | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Intravenous Injections | 2476.00 | 2952.36 | 3520.37 | 4197.64 | 5005.22 | 5968.16 | 7116.34 | 8485.41 | 10117.86 | 12064.35 | 14385.30 |
| Intrathecal Injections | 1547.50 | 1845.59 | 2201.11 | 2625.10 | 3130.75 | 3733.81 | 4453.02 | 5310.76 | 6333.70 | 7553.67 | 9008.61 |
| Subcutaneous Injections | 1547.50 | 1839.70 | 2187.05 | 2599.99 | 3090.87 | 3674.42 | 4368.13 | 5192.79 | 6173.10 | 7338.45 | 8723.76 |
| Other Delivery Methods | 619.00 | 735.88 | 874.82 | 1039.99 | 1236.35 | 1469.77 | 1747.25 | 2077.11 | 2469.24 | 2935.38 | 3489.50 |
Antisense and RNAi Therapeutics Market Size By Region 2024 to 2034 (USD )
| Region | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | 2476.00 | 2953.10 | 3522.12 | 4200.78 | 5010.20 | 5975.58 | 7126.95 | 8500.16 | 10137.93 | 12091.25 | 14420.91 |
| Asia Pacific | 1547.50 | 1847.07 | 2204.62 | 2631.37 | 3140.73 | 3748.65 | 4474.24 | 5340.25 | 6373.85 | 7607.48 | 9079.83 |
| Europe | 1238.00 | 1472.49 | 1751.40 | 2083.13 | 2477.68 | 2946.96 | 3505.12 | 4168.97 | 4958.55 | 5897.66 | 7014.61 |
| Latin America | 495.20 | 586.93 | 695.64 | 824.46 | 977.11 | 1158.00 | 1372.34 | 1626.30 | 1927.21 | 2283.74 | 2706.15 |
| Middle East and Africa | 433.30 | 513.93 | 609.56 | 722.97 | 857.47 | 1016.96 | 1206.10 | 1430.39 | 1696.35 | 2011.72 | 2385.68 |
Antisense and RNAi Therapeutics Market
Proceed To Buy
Proceed To CheckoutMake Every Move Strategic. Get Insights, Fully Customized
- On-Demand Metrics & KPIs
- Industry-Specific Dashboards
- Quick Turnaround, No Compromises
Quick Contact
- NA : +1 804 441 9344
- APAC : +91 9356 9282 04
- EU : +44 7782 560 738
- sales@precedenceresearch.com
